Saba Sile

Teprotumumab for the Treatment of Active Thyroid Eye Disease

Raymond S. Douglas, George J. Kahaly, Amy Patel et al. · New England Journal of Medicine · 2020 · 700 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +11

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials

George J. Kahaly, Raymond S. Douglas, Robert J. Holt et al. · The Lancet Diabetes & Endocrinology · 2021 · 179 citations

Medicine, Endocrinology, Ophthalmology +10

Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial

Nicola Longo, Cary O. Harding, Barbara K. Burton et al. · The Lancet · 2014 · 167 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +6

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment

Raymond S. Douglas, George J. Kahaly, Shoaib Ugradar et al. · Ophthalmology · 2021 · 158 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +13

Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema

James Brian Byrd, Karine Touzin, Saba Sile et al. · Hypertension · 2007 · 147 citations · Full text

Life Sciences, Pharmacology, Clinical Pharmacology +12